JP2022509525A5 - - Google Patents
Info
- Publication number
- JP2022509525A5 JP2022509525A5 JP2021548548A JP2021548548A JP2022509525A5 JP 2022509525 A5 JP2022509525 A5 JP 2022509525A5 JP 2021548548 A JP2021548548 A JP 2021548548A JP 2021548548 A JP2021548548 A JP 2021548548A JP 2022509525 A5 JP2022509525 A5 JP 2022509525A5
- Authority
- JP
- Japan
- Prior art keywords
- raspatercept
- approximately
- subject
- sotatercept
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862753379P | 2018-10-31 | 2018-10-31 | |
| US62/753,379 | 2018-10-31 | ||
| PCT/US2019/058803 WO2020092523A1 (en) | 2018-10-31 | 2019-10-30 | TREATMENT OF ANEMIA DUE TO VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES IN SUBJECTS WITH RING SIDEROBLASTS USING ACTIVIN-ACTRll LIGAND TRAPS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022509525A JP2022509525A (ja) | 2022-01-20 |
| JP2022509525A5 true JP2022509525A5 (https=) | 2022-11-07 |
| JP7663502B2 JP7663502B2 (ja) | 2025-04-16 |
Family
ID=70464629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548548A Active JP7663502B2 (ja) | 2018-10-31 | 2019-10-30 | 環状鉄芽球が見られる対象における非常に低リスク、低リスクまたは中程度のリスクの骨髄異形成症候群による貧血の、アクチビン－ａｃｔｒｉｉリガンドトラップを用いた治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210346464A1 (https=) |
| EP (1) | EP3873501A4 (https=) |
| JP (1) | JP7663502B2 (https=) |
| KR (1) | KR20210088548A (https=) |
| CN (1) | CN112969471A (https=) |
| WO (1) | WO2020092523A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| JP2018501307A (ja) | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018501307A (ja) * | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| US20180125928A1 (en) * | 2015-05-13 | 2018-05-10 | Celgene Corporation | Treatment of beta-thalassemia using actrii ligand traps |
| PL3638243T3 (pl) * | 2017-06-14 | 2025-02-10 | Celgene Corporation | Sposoby leczenia mielofibrozy związanej z nowotworem mieloproliferacyjnym i niedokrwistości |
-
2019
- 2019-10-30 JP JP2021548548A patent/JP7663502B2/ja active Active
- 2019-10-30 WO PCT/US2019/058803 patent/WO2020092523A1/en not_active Ceased
- 2019-10-30 KR KR1020217011918A patent/KR20210088548A/ko active Pending
- 2019-10-30 CN CN201980071973.5A patent/CN112969471A/zh active Pending
- 2019-10-30 EP EP19878490.2A patent/EP3873501A4/en active Pending
- 2019-10-30 US US17/289,420 patent/US20210346464A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022509525A5 (https=) | ||
| US20220054531A1 (en) | Treatment of acute myeloid leukemia with hypomethylating agents and 2-o, 3-o desulfated heparinoids | |
| CN104411316B (zh) | 骨髓抑制的治疗 | |
| KR101074430B1 (ko) | 항암 용도를 위한 독소루비신 제형 | |
| AU2021212068B2 (en) | Uses of IL-12 as an hematopoietic immunotherapy (HIT) | |
| US20210346464A1 (en) | TREATMENT OF ANEMIA DUE TO VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES IN SUBJECTS WITH RING SIDEROBLASTS USING ACTIVIN-ACTRll LIGAND TRAPS | |
| Shi et al. | Hypoxia-activated cascade nanovaccine for synergistic chemoembolization-immune therapy of hepatocellular carcinoma | |
| ES2921858T3 (es) | Régimen de cladribina en el tratamiento de la esclerosis múltiple | |
| EP3609471B1 (en) | Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4- methoxybenzylsulphone with enhanced stability and bioavailability | |
| US20220233652A1 (en) | Pharmaceutical Compositions Comprising Integration-Promoting Peptides | |
| CN109662968A (zh) | 含A-失碳-5α雄甾烷化合物的升白制剂及其应用 | |
| WO2009078474A1 (en) | An agent for reducing a side effect of an anticancer drug | |
| Brugnatelli et al. | Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma | |
| JP6172880B1 (ja) | ダルベポエチンを含む液体医薬組成物 | |
| US20150250723A1 (en) | Non-pegylated liposomal doxorubicin combinations for the treatment of triple negative breast cancer | |
| HK40095413B (en) | (e)-2,4,6-trimethoxystyryl-3- [(carboxymethyl)amino]-4- methoxybenzylsulphone, sodium salt for use in a method of treating a solid tumor cancer | |
| HK40095413A (en) | (e)-2,4,6-trimethoxystyryl-3- [(carboxymethyl)amino]-4- methoxybenzylsulphone, sodium salt for use in a method of treating a solid tumor cancer | |
| CN1622813A (zh) | 治疗和二级预防深静脉血栓患者静脉血栓栓塞用的药物I draparinux (San0rg 34006) | |
| Engle et al. | The Pharmacist Practitioner’s Role in Biotechnology: Clinical Application of Biotechnology Products | |
| HK40040601A (en) | (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone for use in a method of treating conditions mediated by abnormal cell proliferation | |
| CN104203252A (zh) | 注射剂用组合物 | |
| HK40033899A (en) | Formulation containing a-decarbonized-5alpha androstane compound for increasing white blood cell and use thereof | |
| Kerbel et al. | Metronomic Antiangiogenic Chemotherapy: Questions and Answers | |
| HK40022425A (en) | Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4- methoxybenzylsulphone with enhanced stability and bioavailability | |
| HK40022425B (en) | Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4- methoxybenzylsulphone with enhanced stability and bioavailability |